ArticleVirchows Archiv : an international journal of pathology1994
The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
Article in Virchows Archiv : an international journal of pathology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 125 citations in OpenAlex.
- Prognostic markers for colorectal cancer: expression of P53 and BCL2.World journal of surgery · 1997Trial
- An insight into the anticancer mechanism of3 Biotech · 2019Article
- BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.Cancer research and treatment · 2018Article
- Article
- The essential role of evasion from cell death in cancer.Advances in cancer research · 2011Review
- Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.Molecular oncology · 2008Article
- Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.Breast cancer research : BCR · 2008Article
- Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study.Digestive diseases and sciences · 2003Article
- Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer.Pathology oncology research : POR · 2003Article
- p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.Journal of clinical pathology · 2002Article
- Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score.Sao Paulo medical journal = Revista paulista de medicina · 2001Article
- Number of apoptotic cells as a prognostic marker in invasive breast cancer.British journal of cancer · 2000Article
- Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.Pathology oncology research : POR · 2000Article
- A role for intracellular immunization in chemosensitization of tumor cells?Gene therapy · 1999Review
- The epidermal growth factor receptor in breast cancer.Journal of mammary gland biology and neoplasia · 1997Review
- Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis.Virchows Archiv : an international journal of pathology · 1997Article
- Immunohistochemical expression of bcl-2 protein in squamous cell carcinoma and basaloid carcinoma of the esophagus.Surgery today · 1997Article
- Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas.Virchows Archiv : an international journal of pathology · 1997Article
- Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report.British journal of cancer · 1997Article
- Bcl-2 immunoreactivity in salivary gland neoplasms is unrelated to the expression of mRNA for natural killer cell stimulatory cytokines interleukin (IL)-2 and IL-12.Virchows Archiv : an international journal of pathology · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BCL-2 protein plays a pivotal role in overriding programmed cell death (apoptosis), thus favouring a prolonged survival of normal and neoplastic cells. Expression of the bcl-2 gene has been documented in some human tumours (non-Hodgkin's lymphomas and prostatic adenocarcinomas), but findings in breast carcinomas have not been reported. We have used the monoclonal antibody 124 to investigate BCL-2 expression in 212 breast carcinomas, and to correlate it with the oestrogen (ER), progesterone (PR) and epidermal growth factor receptor (EGFR) status, and with other clinicopathological variables including tumour type, grade, stage, growth fraction (as evaluated by Ki-67 immunostaining), and p53 accumulation. Of the 212 carcinomas, 173 (81.6%) exhibited BCL-2 immunoreactivity in more than 25% of the neoplastic cells. BCL-2 immunoreactivity was strongly correlated with ER and PR expression (P < 0.00001), with the lobular type (P = 0.012) and with better differentiated neoplasms (P = 0.00003), whereas it was inversely correlated with EGFR (P < 0.00001), p53 (P = 0.0004) and Ki-67 (P = 0.0002) immunoreactivities. No association was found with tumour stage (T and N categories). We conclude that bcl-2 expression in breast cancers is related to the oestrogen-dependent transcription pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.